Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-Apple, GM, Google, Halliburton, Hasbro, Pfizer, Sprint

Mon, 21st Apr 2014 11:43

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

April 21 -

** HALLIBURTON CO, Thursday close $60.9

The oilfield services company reported a profit for thefirst quarter, compared with a loss a year earlier when itbooked a pre-tax charge of $1 billion related to the Gulf ofMexico spill.

** HASBRO INC, Thursday close $54.61

The toymaker reported a quarterly profit, compared with ayear-ago loss, helped by strong demand for its toys for girls.The company's first-quarter revenue rose 2 percent to $679.5million.

** GENERAL MOTORS CO, Thursday close $33.98

The U.S. car giant plans to invest $12 billion in China from2014 to 2017 and build more plants next year as it competes withaggressive rivals in the world's largest auto market.

** NEWMONT MINING CORP, Thursday close $23.54

The talks between Barrick Gold Corp and NewmontMining over a combination that would create a gold miningbehemoth have hit a snag, but two sources close to the situationsay the companies remain keen on a deal and discussions arelikely to resume.

** PFIZER INC, Thursday close $30.25

The U.S. pharmaceutical giant has approached British rivalAstraZeneca Plc to propose a 60 billion pound ($101billion) takeover, Britain's Sunday Times reported.

** APPLE INC, Thursday close $524.94

** GOOGLE INC, Thursday close $543.34

Apple and Google are wooing game developers to ensure thattop game titles arrive first on devices powered by theirrespective operating system, the Wall Street Journal reported,citing people familiar with the matter.

** KRAFT FOODS GROUP INC, Thursday close $56.91

Kraft Foods is recalling about 96,000 pounds of Oscar MayerClassic Wieners because the packages may instead contain ClassicCheese Dogs made with milk, a known allergen.

** COMCAST CORP, Thursday close $49.1

** CHARTER COMMUNICATIONS INC, Thursday close$56.91

Comcast is in talks with Charter Communications over sellingor spinning off roughly 3 million subscribers worthapproximately $18 billion to $20 billion as part of thedivestitures related to its $45.3 billion takeover of TimeWarner Cable, according to a source familiar with thematter.

** VIMPELCOM LTD, Thursday close $9

Russia's Vimpelcom has resolved a long-running dispute withthe Algerian government by selling it a majority stake in thecountry's biggest telecoms operator for $2.6 billion, while itwill keep control and slash debt.

** AMERICAN TOWER CORP, Thursday close $82.65

Indian conglomerate Reliance Industries Ltd' telecommunications unit, which holds nationwide 4G permits, hasagreed to lease mobile phone masts from infrastructure providerAmerican Tower Corp's local arm, the companies said in astatement on Monday.

** WALT DISNEY CO, Thursday close $79.99

Walt Disney Co's cable networks are expected to record highsingle-digit growth in operating income and domestic affiliaterevenue from fiscal 2014 through 2016, Chief Financial OfficerJay Rasulo told investors on Thursday.

** SPRINT CORP, Thursday close $8.52

** T-MOBILE US INC, Thursday close $30.4

A possible merger between Sprint and T-Mobile could promptU.S. regulators to rewrite rules they are now weighing for a2015 auction of airwaves, according to sources familiar with theproposed regulations.

** LULULEMON ATHLETICA INC, Thursday close $51.71

A U.S. judge has issued final dismissals of lawsuitsaccusing Lululemon and various company officials of defraudingshareholders by concealing defects in yoga pants.

** CHINDEX INTERNATIONAL INC, Thursday close $22.94

Chinese drugmaker Shanghai Fosun Pharmaceutical Group Co Ltd has raised its offer for U.S.-listed ChindexInternational Inc by 15 percent to $223.6 million aftera bidding war for the China-focused hospital chain.

** ATHENAHEALTH, Thursday close $145.58

The healthcare IT services company on Thursday reportedfirst-quarter adjusted earnings and revenue that fell below WallStreet estimates.

Three brokerages, including Oppenheimer, Deutsche Bank andB. Riley cut their price targets on the company' stock, citingweakness in its Epocrates business - a mobile medicalapplication.

** SAREPTA THERAPEUTICS INC, Thursday close $24.4

The company said it would start new trials to revive thechance of approval for its experimental muscle disorder drugafter the U.S. Food and Drug Administration advised the companyto submit new safety and efficacy data.

** SELECT COMFORT CORP, Thursday close $17.75, +3.3 pct after market

The specialty mattress maker on Thursday reportedfirst-quarter sales that beat analysts' estimates, helped by a 2percent rise in comparable sales.

** PEOPLE'S UNITED FINANCIAL INC, Thursday close-100.00

Brokerage Keefe Bruyette & Woods cut the lender's targetprice to $14.50 from $15, citing low profitability until thecompany improves return on assets and efficiency ratio.

** PRIVATEBANCORP INC, Thursday close $29.59

KBW raised its price target on the stock to $34 from $33after the bank reported better-than-expected first quarterresults on Thursday, helped by commercial loan growth.

** LINEAR TECHNOLOGY CORP, Thursday close $46.37

The analog chipmaker said on Thursday it expects revenue togrow 2-6 percent from $348 million in the third quarter, that is$355-$369 million. Analysts on average were expecting revenue of$365 million, according to Thomson Reuters I/B/E/S.

** RADIOSHACK CORP, Thursday close $0

The struggling U.S. electronics chain is mired in talks withits lenders over its plans to close about 1,100 stores,complicating its turnaround efforts, the Wall Street Journalreported, citing sources close to the talks.

RadioShack, which operates about 4,300 stores in the UnitedStates, said in March that the plan needed permission from itslenders, adding that its credit agreements allowed it to closeonly about 200 stores without the approval of lead lenders, theJournal said late on Wednesday. (http://r.reuters.com/vyg68v)

The company reported a wider quarterly loss and a huge dropin sales during the holiday season.

** WEIBO CORP, Thursday close $20.24

The Chinese Twitter-like messaging service company'sU.S.-listed shares were up premarket on Monday after they soared19 percent on their debut on Thursday.

** BIOGEN IDEC INC, Thursday close $290.54

Biogen is pricing its newly approved long-acting hemophiliadrug, Alprolix, to cost U.S. patients, and insurers, about thesame per year as older, less convenient therapies whose pricecan reach about $300,000 annually.

The move could pressure rivals such as Pfizer Inc tolower prices for existing hemophilia treatments, which providepatients with life-saving infusions of a blood clotting agent,according to doctors and industry analysts.

** UNITEDHEALTH GROUP INC, Thursday close $75.78

The largest U.S. health insurer, said it spent more than$100 million to cover a pricey new hepatitis C drug from GileadSciences Inc GILD.O in its first three months on the market, anamount that was "multiple" times what it had expected.

** ABBOTT LABORATORIES, Thursday close $38.93

An Abbott Laboratories spinoff urged a federal appealscourt to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutionalprotections for gays and lesbians.

** PLATINUM UNDERWRITERS HOLDINGS LTD, Thursdayclose $62.16, -100.00 pct premarket

Brokerage Keefe Bruyette & Woods raised the reinsuranceprovider's target price to $69 from $67, after the company'searnings for the quarter ended March 31 beat analysts' estimateswith strong underwriting, investing, and capital managementperformance. The company reported earnings per share of $2.27,higher than analysts' average estimate of $1.28, according toThomson Reuters I/B/E/S. [ID: nPn5HRfMd] (Compiled by Rohit T.K. in Bangalore; Editing by Joyjeet Das)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.